پلاسمینوژن

The emergence of thrombolytic drugs has opened new horizons in the treatment of patients with acute ischemic stroke, and this study was conducted with the aim of evaluating the barriers of receiving tissue plasminogen activator in patients with acute ischemic stroke in Imam Khomeini Hospital of Urmia.

This descriptive-analytical, cross-sectional study was conducted from April 21, 2015 to March 19, 2016 on patients with acute ischemic stroke referred to the emergency department of Imam Khomeini Hospital in Urmia using census sampling method. To collect data, a checklist containing demographic information was used. After collecting the data, it was entered into SPSS 18 and analyzed with the help of descriptive statistics.

In this study, the results showed that out of 100 patients, most of the participants were male (58%)58 and the rest were female, and the average age was 63.71±17.3 years, and 86% were in the age range of 18-80 years, which was the appropriate age to receive or thrombolytics. and the rest were over 80 years old. The fastest visit time was 25 minutes and the latest was 10080 minutes (168 hours). Among these 40 people, only four people (40%) were in the golden time period of thrombolytic drug, i.e. Three hours from the onset of symptoms to the final evaluation. Among the four people who were placed in the golden time, in 50% of the cases there was a history of taking anticoagulants, in 25% a history of head injury, in 50% of the blood sugar less than 50 and finally 1 person (25% of the people placed in the golden time) that is, 1% of all patients were eligible to receive rtPA. About 24% of patients had NIHSS<4 and 2% had NIHSS>25, and the average number obtained was 10.

The most important obstacle in the timely initiation of thrombolytic therapy is the delay in visiting the emergency room. Therefore, public education in order to improve the level of general awareness of the society can be effective in reducing this time delay.

Coronary artery disease (CAD) is one of the major causes of mortality and morbidity. It is characterized by the activation and aggregation of the platelet, thrombus formation and myocardial infarction. During recent years, many epidemiological studies on risk factors of CAD have been performed which are fibrinogen, lipoprotein (a), and hemocystein as new CAD risk factors. The aim of the present study was to evaluate of plasminogen, fibrinogen and plasmin (PAP) levels in plasma including in patients of non-diabetic and smoker as the hemostatic parameters and their association with CAD to prevent progression of disease.

In this study selected 120 subjects including 60 patients who underwent coronary angiography and 60 controls from blood donors of blood bank who had no history of CAD and liver disease and cancer. To determined Plasma levels plasminogen and PAP used ELISA Procedure (Bioassay technology laboratory kit) and plasma level of fibrinogen used Clauss method by kit of Mahsa yaran.

Plasma levels of plasminogen and plasmin anti plasmin (PAP) in patients with CAD were found to be significantly lower than control group (p

Elevated plasma levels of fibrinogen participate in atherogenesis leading to CAD. These finding suggested plasma level of fibrinogen can be useful as a diagnostic and monitoring marker in patients with CAD. Plasmin and plasminogen deficiency may participate in progressing CAD and thrombus formation and impaired fibrinolysis.